PMID- 29224109
OWN - NLM
STAT- MEDLINE
DCOM- 20180604
LR  - 20180604
IS  - 0065-2598 (Print)
IS  - 0065-2598 (Linking)
VI  - 1043
DP  - 2017
TI  - Testosterone Therapy and Glucose Homeostasis in Men with Testosterone Deficiency 
      (Hypogonadism).
PG  - 527-558
LID - 10.1007/978-3-319-70178-3_23 [doi]
AB  - Since the early 1990s, it has been recognized that testosterone (T) levels are 
      lower in men with type 2 diabetes mellitus (T2DM) compared with nondiabetic men 
      (controls). Hypogonadism has been reported in approximately 50% of men with T2DM 
      with robust correlations with measures of obesity, such as waist circumference 
      and body mass index (BMI). In longitudinal studies, hypogonadism has been 
      identified as a predictor of incident T2DM. Experimental withdrawal of T led to 
      acute decreased insulin sensitivity, which can be reversed by normalization of T 
      concentrations. Androgen deprivation therapy, commonly used in men with advanced 
      prostate cancer, increases the risk of incident T2DM significantly.While 
      short-term studies of T therapy in hypogonadal men with T2DM show only minor 
      effects, long-term administration of T leads to meaningful and sustained 
      improvements of glycemic control with parallel reductions in body weight and 
      waist circumference. The more insulin-resistant and obese a patient is at the 
      time of initiation of T therapy, the more improvements are noted. The observed 
      effects are likely mediated by the increase in lean body mass invariably achieved 
      by T therapy, as well as the improvement in energy and motivation, referred to as 
      the psychotropic effects of T. As recommended by various guidelines, measuring T 
      levels and, if indicated, restoring men's T levels into the normal physiological 
      range can have a substantial impact on ameliorating T2DM in hypogonadal men.
FAU - Saad, Farid
AU  - Saad F
AD  - Global Medical Affairs Andrology, Bayer AG, Berlin, Germany. 
      farid.saad@bayer.com.
AD  - Gulf Medical University School of Medicine, Ajman, United Arab Emirates. 
      farid.saad@bayer.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Adv Exp Med Biol
JT  - Advances in experimental medicine and biology
JID - 0121103
RN  - 0 (Blood Glucose)
RN  - 3XMK78S47O (Testosterone)
SB  - IM
MH  - Blood Glucose/*drug effects/metabolism
MH  - Body Composition/drug effects
MH  - Diabetes Mellitus, Type 2/*blood/diagnosis/epidemiology
MH  - Homeostasis
MH  - *Hormone Replacement Therapy/adverse effects
MH  - Humans
MH  - Hypogonadism/blood/diagnosis/*drug therapy/epidemiology
MH  - Insulin Resistance
MH  - Male
MH  - Risk Factors
MH  - Testosterone/adverse effects/blood/*deficiency/*therapeutic use
MH  - Treatment Outcome
EDAT- 2017/12/11 06:00
MHDA- 2018/06/05 06:00
CRDT- 2017/12/11 06:00
PHST- 2017/12/11 06:00 [entrez]
PHST- 2017/12/11 06:00 [pubmed]
PHST- 2018/06/05 06:00 [medline]
AID - 10.1007/978-3-319-70178-3_23 [doi]
PST - ppublish
SO  - Adv Exp Med Biol. 2017;1043:527-558. doi: 10.1007/978-3-319-70178-3_23.